Sun Pharma added to Citi’s pan-Asia focus list with 35% upside

Brokerage firm Citi expects Sun Pharma’s innovation revenues to climb to $3.2 billion by FY30, up from $1.2 billion in FY25.

Leave a Reply

Your email address will not be published. Required fields are marked *